RSS   Newsletter   Contact   Advertise with us

ImmunoVaccine appoints Frederic Ors as chief executive officer

Share on Twitter Share on LinkedIn
Staff writer | Halifax, NS, Canada | April 18, 2016
ImmunoVaccineApril 18, 2016, Halifax, NS, Canada - ImmunoVaccine, a biotechnology company, appointed Frederic Ors as chief executive officer, and will nominate him and Andy Sheldon to the board of directors.
Mr. Ors has been serving as Immunovaccine's Acting Chief Executive Officer since last month and as Chief Business Officer since April 2015.

Prior to Immunovaccine, Mr. Ors spent 13 years at Medicago in Quebec, most recently as Vice President of Business Development and Strategic Planning. He has also served as the manager of intellectual property and licensing for Paris Diderot University, a complex of 150 labs, two hospitals and 2,300 scientists in Paris.

Mr. Ors earned his bachelor's degree in biology and his master's degree in management of innovation projects in biotechnology at the University of Angers.

Mr. Sheldon has been President and Chief Executive Officer of Medicago since August 2003. He has 30 years of experience in the pharmaceutical industry, and was named CEO of the Year by the Vaccine Industry Excellence awards at the World Vaccine Congress in April 2012.

Before joining Medicago, Mr. Sheldon served as Vice President, Sales and Marketing, of Shire Biologics.

Mr. Sheldon has a bachelor's degree in agricultural sciences from Universite Laval, Quebec City, and a bachelor's of science degree with honors in biological sciences from the University of East Anglia, in Norwich, England.